PMID: 6870220May 1, 1983Paper

Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis

Antimicrobial Agents and Chemotherapy
B E MageraB Postic

Abstract

Vancomycin pharmacokinetics were studied in four patients with peritonitis undergoing chronic intermittent peritoneal dialysis. Serum levels exceeding 4.0 micrograms/ml were maintained for 8 and 13 days after a single 1-g intravenous dose. Vancomycin serum concentrations measured before, during, and upon completion of dialysis revealed no appreciable decline. Peritoneal fluid concentrations in two patients exceeded 4.0 micrograms/ml for more than 12 days.

References

Jun 1, 1978·Annals of Internal Medicine·F V Cook, W E Farrar

Citations

Feb 1, 1984·European Journal of Clinical Microbiology·B B Farber
Dec 13, 1997·Pharmacology & Toxicology·B A Osman, S Q Lew
May 1, 1984·Antimicrobial Agents and Chemotherapy·R D BlevinsG R Matzke
Jun 1, 1984·Antimicrobial Agents and Chemotherapy·G BenoniG P Velo
Jun 1, 1988·Antimicrobial Agents and Chemotherapy·K A RodvoldL J Riff
Nov 3, 2011·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Richard FishStanley L S Fan
Jan 1, 1988·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D L Brown, L S Mauro
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Aug 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G B AppelG L Cooper
Feb 18, 2020·Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis·Edwin LamJingjing Zhang
Apr 30, 2019·Journal of Clinical Pharmacy and Therapeutics·María José Company-AlbirJosé Luis Poveda
Oct 1, 1986·Drug Intelligence & Clinical Pharmacy·M J Rybak, S C Boike
Jul 1, 1986·Pharmacotherapy·R P Cheung, J T DiPiro

Related Concepts

Peritoneal Fluid (Body Substance)
Peritoneal Dialysis
Secondary Peritonitis
AB-Vancomycin

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.